Loading...
•
Mar 31, 2024
Adaptimmune Q1 2024 Earnings Report
Adaptimmune reported its Q1 2024 financial results and business updates.
Key Takeaways
Adaptimmune reported a revenue of $5.7 million for the first quarter ended March 31, 2024, compared to $47.6 million for the same period in 2023. The company's cash and cash equivalents were $140.7 million as of March 31, 2024. Adaptimmune believes its cash runway will extend into late 2025, supported by anticipated revenues from afami-cel and other income sources.
Afami-cel BLA was accepted by the U.S. FDA for advanced synovial sarcoma treatment with priority review and a PDUFA date of August 4th, 2024.
Commercial and manufacturing infrastructure is in place to support the afami-cel commercial launch upon approval.
Data from the SPEARHEAD-1 pivotal trial with afami-cel was published in The Lancet.
Cash runway extends into late 2025, supported by current cash, afami-cel revenues, and other income sources.
Revenue by Segment
Forward Guidance
The company believes that its existing cash, cash equivalents and marketable securities, together with anticipated revenues from the launch of afami-cel, expected future income from partners and other non-dilutive capital sources including the Company’s new debt facility with Hercules Capital announced earlier today, will fund the Company’s current operations into late 2025
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...